Professor Sergio Rutella recently delivered two talks at the 65th American Society of Hematology (ASH) Meeting in San Diego. One regarded a study delivered in collaboration with academics from Washington University and with Wugen, a pharmaceutical company sponsoring an early-phase clinical trial of a specific population of immune cells (NK cells) expected to efficiently kill tumour cells. He highlighted the unique characteristics of NK cells making them an ideal candidate to eradicate leukaemia.
The second presentation reported on a common genetic abnormality (a change in one specific gene called TP53) and how this gene variant potentially affects the ability of a patient’s immune system to get rid of cancer cells. Professor Rutella also moderated a session on acute myeloid leukaemia.
|